LowLATS2mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers
Yuri Takahashi, Yasuo Miyoshi, Koji Morimoto, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo NoguchiVolume:
133
Language:
english
Pages:
9
DOI:
10.1007/s00432-007-0194-0
Date:
August, 2007
File:
PDF, 492 KB
english, 2007